Tenax pauses LEVEL-2 enrollment to refine TNX-103 patient selection after the initial trial missed its primary walking ...
SYCUME met its Phase 3 primary endpoint for inactive thyroid eye disease, showing significant proptosis reduction versus ...
Clinical data teams now prioritize AI validation and human oversight in regulatory workflows, following FDA guidance on ...
Sionna advances SION-451/SION-2222 combo into Phase 2a trial for cystic fibrosis, building on insights from prior SION-719 ...
EMA's ACT EU advice pilot becomes permanent in January 2027, giving EU sponsors consolidated multi-country feedback before CTA submission. Here's what ...
Patient-owned health data model reduces clinical trial recruitment redundancy by enabling persistent consent and longitudinal ...
FDA approves Tecentriq for stage III dMMR colon cancer as adjuvant treatment. ATOMIC trial showed improved disease-free survival when added to chemotherapy.
Remibrutinib reduces relapse rates versus teriflunomide in Phase 3 MS trials REMODEL-1 and REMODEL-2, with results presented ...
Jupiter Neurosciences doses first Parkinson's patient in JOTROL Phase 2a trial, testing whether enhanced resveratrol achieves ...
Enfortumab vedotin-pembrolizumab shows durability advantage over chemotherapy at three-year follow-up in bladder cancer trial ...
Ribo files EU Trial Application for RBD3133, an siRNA targeting INHBE for obesity treatment backed by human genetic evidence.
FDA approves Rhapsido (remibrutinib) for symptomatic dermographism, the first prescription treatment for adults with the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results